Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Neoplasms, Nerve Tissue 2Neoplasms 2Glioma 2Glioblastoma 2Brain Neoplasms 2

Interventions

Magnetic Resonance Spectroscopy 23Temozolomide 22Specimen Handling 13Radiotherapy 12Biopsy 9X-Rays 8Radiation 8trametinib 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Bevacizumab 6larotrectinib 4erdafitinib 4dabrafenib 4abemaciclib 4ulixertinib 3palbociclib 3olaparib 3Surgical Procedures, Operative 3Nivolumab 3D2C7-(scdsFv)-PE38KDEL 3Cyclophosphamide 3tipifarnib 2tazemetostat 2selpercatinib 2pembrolizumab 2mirdametinib 2lutetium Lu 177 dotatate 2ivosidenib 2fluorodopa F 18 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Glioma × contrast agent BR1 × 90 days × Clear all
NCT06329570 2026-04-09

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

NaviFUS Corporation

Phase 1/2 Recruiting
10 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue

NCT06496971 2026-04-09

A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients

NaviFUS Corporation

Phase 3 Recruiting
32 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue

Data powered by HemOnc (CC BY 4.0) Colophon âš¡